From the College of Nursing, University of Wisconsin-Milwaukee, Milwaukee, WI (AAL, HA); School of Nursing, University of Wisconsin, Madison, WI (JML); Behavior Analysis and Therapy, Southern Illinois University, Carbondale, IL (RR); and Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI (ST).
J Addict Med. 2024;18(2):153-159. doi: 10.1097/ADM.0000000000001260. Epub 2024 Jan 3.
We are in the midst of an overdose epidemic that has grown during the concurrent COVID-19 pandemic. In Wisconsin, overdose deaths increased 11-fold from 2000 to 2020, with over 1200 deaths in 2020. Because of disparities in substance use initiation, relapse, and treatment success among racially minoritized women, this study's purpose was to investigate overdose death rates among Black and Indigenous women in Wisconsin from 2018 to 2020.
Overdose death rates were examined under the following parameters: sex, race (Black, Indigenous, White), age, year, and manner of death. Logistic regression analysis was also conducted looking at death count data, with race, age, and year as potential predictor variables.
Death rates (per 100,000) in 2018 were 14.1 (12.6-15.5) for White women, 20.8 (14.7-26.9) for Black women, and 26.5 (10.0-42.9) for Indigenous women; these rates increased in 2020 to 16.4 (14.8-17.9), 32.5 (25.0-40.0), and 59.9 (35.8-84.0) for White, Black, and Indigenous women, respectively. Regression findings illustrated that being Black or Indigenous and aged 15 to 44 or 45 to 64 years were significantly more likely to die from most causes of death (any drug, any opioid, prescription opioid, heroin, synthetic opioids, and cocaine; adjusted odds ratios > 1.25, P s < 0.001).
This study confirms that deaths in Wisconsin are disproportionately higher in female minoritized populations. Understanding the complex intricacies between the impacts of the COVID-19 pandemic coupled with barriers to treatment access or acceptability in these populations is urgently needed. It will take a multipronged approach to address the overdose epidemic and better serve these marginalized, vulnerable populations.
我们正处于一场与同时发生的 COVID-19 大流行有关的药物过量流行之中。在威斯康星州,从 2000 年到 2020 年,药物过量死亡人数增加了 11 倍,2020 年有超过 1200 人死亡。由于少数族裔女性在物质使用开始、复发和治疗成功方面存在差异,因此本研究的目的是调查 2018 年至 2020 年期间威斯康星州黑人和土著女性的药物过量死亡率。
在以下参数下检查药物过量死亡率:性别、种族(黑人、土著、白人)、年龄、年份和死亡方式。还进行了逻辑回归分析,研究死亡人数数据,种族、年龄和年份是潜在的预测变量。
2018 年,白人女性的死亡率(每 10 万人)为 14.1(12.6-15.5),黑人女性为 20.8(14.7-26.9),土著女性为 26.5(10.0-42.9);这些比率在 2020 年分别增加到 16.4(14.8-17.9)、32.5(25.0-40.0)和 59.9(35.8-84.0),对于白人、黑人、和土著女性。回归结果表明,黑人或土著人、年龄在 15 至 44 岁或 45 至 64 岁之间,死于大多数死因(任何药物、任何阿片类药物、处方阿片类药物、海洛因、合成阿片类药物和可卡因)的可能性显著更高(调整后的优势比>1.25,P s <0.001)。
本研究证实,威斯康星州的死亡人数在少数族裔女性人口中不成比例地更高。迫切需要了解 COVID-19 大流行的影响以及这些人群中治疗机会或可接受性方面的障碍之间的复杂关系。需要采取多管齐下的方法来解决药物过量流行问题,并更好地为这些边缘化、弱势群体服务。